The effect of hepatitis C virologic clearance on cardiovascular disease biomarker lipoprotein-associated phospholipase A2 and its relation to serum lipids
نویسندگان
چکیده
Abstract Background Chronic hepatitis C virus (HCV) infection has been linked to cardiovascular disease (CVD). However, CVD risk prediction in chronic HCV-infected patients is problematic as the prevalence of different cardiac biomarkers these currently unknown. Serum lipids, which are routinely used traditional scores, may underestimate patients, while non-hepatically produced biomarkers, including lipoprotein-associated phospholipase A2 (Lp-PLA2), better reflect risk. In this study, we aimed evaluate effect sustained virologic response (SVR) on risk, predicted by Lp-PLA2 mass comparison with serum lipid levels. Results Ninety were enrolled study. was measured before and after HCV treatment via direct-acting antivirals compared changes lipids Framingham score (FRS). The level categorized into high (>235 ng/ml) or low (≤235 ng/ml). Mean significantly decreased from 322.37 ± 79.15 ng/ml 263.79 51.804 SVR, number high-risk dropped 82.22 60% treatment. Total cholesterol, low-density lipoprotein, high-density lipoprotein levels low/optimal at baseline (170 40.34 mg/dl, 71.98 24.12 48.43 6.79 mg/dl) increased SVR (195.66 55.68 103.24 46.57 53.91 8.67 mg/dl). According FRS, only 30% moderate/high insignificantly declined 28.89% post-treatment. Conclusion be a predictor patients. Furthermore, reduce hepatic inflammation consequently
منابع مشابه
The Effect of Hepatitis C Virologic Clearance on Cardiovascular Disease Biomarkers in Human Immunodeficiency Virus/Hepatitis C Virus Coinfection
BACKGROUND Successful hepatitis C virus (HCV) treatment may reduce cardiovascular disease (CVD) risk and improve levels of CVD biomarkers produced outside the liver (nonhepatic biomarkers). METHODS Stored serum or plasma from before and 24 weeks after end of HCV treatment (EOT) from human immunodeficiency virus (HIV)/HCV-coinfected subjects who received up to 72 weeks of peginterferon/ribavir...
متن کاملthe effect of oxytetracycline on serum calcium, phosphorus and magnesium in cattle
نتایج این مطالعه نشان می دهد که مقدار کلسیم (یونیزه و تام)، منیزیم و فسفر به طور معنی داری تغییر پیدا کرد به جزء مقدار کلسیم تام و منیزیم در روش داخل عضلانی که تغییر معنی داری نداشته است. بر اساس نتایج این مطالعه می توان نتیجه گیری کرد که اکسی تتراساکلین بر روی مقادیر سرمی کلسیم و منیزیم تأثیر می گذارد باید مقدار این کاتیون ها در بیماران، در هنگامی که اکسی تتراسایکلین استفاده می شود مورد توجه ق...
15 صفحه اولDifferential effect of hypolipidemic drugs on lipoprotein-associated phospholipase A2.
OBJECTIVE Lipoprotein-associated phospholipase A2 (Lp-PLA2) is a predictor for incident atherosclerotic disease. We investigated the effect of 3 hypolipidemic drugs that exert their action through different mechanisms on plasma and lipoprotein-associated Lp-PLA2 activity and mass. METHODS AND RESULTS In 50 patients with Type IIA dyslipidemia were administered rosuvastatin (10 mg daily), where...
متن کاملEffect of Cardiovascular Drugs on the Plasma Levels of Lipoprotein- Associated Phospholipase A2 (Lp-PLA2)
Several lines of evidence suggest that the lipoprotein-associated phospholipase A2 (Lp-PLA2) plays an important role in the pathogenesis of atherosclerotic disease. From a pathophysiological point of view the enzyme bound to apolipoprotein-B-containing lipoproteins (which corresponds to more than 90% of plasma enzymatic activity) may play a proatherogenic role since it generates lysophosphatidy...
متن کاملLipoprotein-Associated Phospholipase A2 – Pathophysiological Role and Clinical Significance as a Cardiovascular Biomarker
Within the last decade, a broad range of biomarkers associated with an increased risk for death and cardiovascular/cerebrovascular endpoints have been identified. Epide‐ miological studies clearly indicate that lipoprotein-associated phospholipase A2 (LpPLA2) has the potential to become clinically useful emerging biomarker in the true sense, linking plaque biology with cardiovascular/cerebrovas...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Egyptian Liver Journal
سال: 2021
ISSN: ['2090-6226', '2090-6218']
DOI: https://doi.org/10.1186/s43066-021-00110-x